Cargando…

Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient

BACKGROUND: Atopic dermatitis is a chronic inflammatory skin disorder, whose symptoms and severity grossly depend on individual trigger factors. The majority of patients are satisfactorily treated with emollients together with topical and systemic therapies. However, treatment failure or long-term s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bormioli, Susanna, Matucci, Andrea, Dies, Laura, Nencini, Francesca, Grosso, Francesca, Maggi, Enrico, Vultaggio, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413441/
https://www.ncbi.nlm.nih.gov/pubmed/30911288
http://dx.doi.org/10.1186/s12948-019-0109-z
_version_ 1783402820913856512
author Bormioli, Susanna
Matucci, Andrea
Dies, Laura
Nencini, Francesca
Grosso, Francesca
Maggi, Enrico
Vultaggio, Alessandra
author_facet Bormioli, Susanna
Matucci, Andrea
Dies, Laura
Nencini, Francesca
Grosso, Francesca
Maggi, Enrico
Vultaggio, Alessandra
author_sort Bormioli, Susanna
collection PubMed
description BACKGROUND: Atopic dermatitis is a chronic inflammatory skin disorder, whose symptoms and severity grossly depend on individual trigger factors. The majority of patients are satisfactorily treated with emollients together with topical and systemic therapies. However, treatment failure or long-term side effects with conventional treatment options can be a significant clinical problem. Recently, novel therapeutic approaches focus on targeting skewed immune responses providing a more effective, and less harmful approach. Among them, variable success has been reported using Omalizumab, when used in combination with classic therapies. This report describes an interesting case of severe adult onset difficult-to-treat atopic dermatitis dramatically improved in response to treatment with Omalizumab. CASE PRESENTATION: We present a case of an adult male with severe allergic atopic dermatitis, with concomitant involvement of the face, neckline, trunk and forearms and systemic symptoms such as diarrhoea with important decrease of his daily quality of life. The patient had been prescribed oral steroids in addition to anti-histamines to no avail. Due to lack of response to classic therapies, strict diet, as well as to treatment with intravenous corticosteroids, an off-label treatment with Omalizumab based on patient weight and total IgE value was proposed. Clear clinical results were observed after only a few weeks with regards to systemic symptoms, and just after 2 months of treatment in regards to skin involvement. CONCLUSIONS: In the majority of treated patients the clinical improvement of cutaneous manifestations is expected after several months of treatment, as skin manifestations are the consequence of a chronic inflammatory process. The outstanding rapid response observed in this case as well as the persistence of the clinical remission suggests that the block of the IgE pathways modulate functions of cells involved in the pathogenic mechanisms of chronic skin inflammation but also in the acute phases observed in the flare-ups of the disease.
format Online
Article
Text
id pubmed-6413441
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64134412019-03-25 Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient Bormioli, Susanna Matucci, Andrea Dies, Laura Nencini, Francesca Grosso, Francesca Maggi, Enrico Vultaggio, Alessandra Clin Mol Allergy Case Report BACKGROUND: Atopic dermatitis is a chronic inflammatory skin disorder, whose symptoms and severity grossly depend on individual trigger factors. The majority of patients are satisfactorily treated with emollients together with topical and systemic therapies. However, treatment failure or long-term side effects with conventional treatment options can be a significant clinical problem. Recently, novel therapeutic approaches focus on targeting skewed immune responses providing a more effective, and less harmful approach. Among them, variable success has been reported using Omalizumab, when used in combination with classic therapies. This report describes an interesting case of severe adult onset difficult-to-treat atopic dermatitis dramatically improved in response to treatment with Omalizumab. CASE PRESENTATION: We present a case of an adult male with severe allergic atopic dermatitis, with concomitant involvement of the face, neckline, trunk and forearms and systemic symptoms such as diarrhoea with important decrease of his daily quality of life. The patient had been prescribed oral steroids in addition to anti-histamines to no avail. Due to lack of response to classic therapies, strict diet, as well as to treatment with intravenous corticosteroids, an off-label treatment with Omalizumab based on patient weight and total IgE value was proposed. Clear clinical results were observed after only a few weeks with regards to systemic symptoms, and just after 2 months of treatment in regards to skin involvement. CONCLUSIONS: In the majority of treated patients the clinical improvement of cutaneous manifestations is expected after several months of treatment, as skin manifestations are the consequence of a chronic inflammatory process. The outstanding rapid response observed in this case as well as the persistence of the clinical remission suggests that the block of the IgE pathways modulate functions of cells involved in the pathogenic mechanisms of chronic skin inflammation but also in the acute phases observed in the flare-ups of the disease. BioMed Central 2019-03-12 /pmc/articles/PMC6413441/ /pubmed/30911288 http://dx.doi.org/10.1186/s12948-019-0109-z Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Bormioli, Susanna
Matucci, Andrea
Dies, Laura
Nencini, Francesca
Grosso, Francesca
Maggi, Enrico
Vultaggio, Alessandra
Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
title Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
title_full Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
title_fullStr Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
title_full_unstemmed Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
title_short Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
title_sort rapid clinical improvement of atopic dermatitis in an omalizumab treated patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413441/
https://www.ncbi.nlm.nih.gov/pubmed/30911288
http://dx.doi.org/10.1186/s12948-019-0109-z
work_keys_str_mv AT bormiolisusanna rapidclinicalimprovementofatopicdermatitisinanomalizumabtreatedpatient
AT matucciandrea rapidclinicalimprovementofatopicdermatitisinanomalizumabtreatedpatient
AT dieslaura rapidclinicalimprovementofatopicdermatitisinanomalizumabtreatedpatient
AT nencinifrancesca rapidclinicalimprovementofatopicdermatitisinanomalizumabtreatedpatient
AT grossofrancesca rapidclinicalimprovementofatopicdermatitisinanomalizumabtreatedpatient
AT maggienrico rapidclinicalimprovementofatopicdermatitisinanomalizumabtreatedpatient
AT vultaggioalessandra rapidclinicalimprovementofatopicdermatitisinanomalizumabtreatedpatient